Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17352482 | 0.84 | CTSD (0.50) | AGERMTNR1ACTSDCHRM2CHRM3 | |
| SCHEMBL13734228 | 0.83 | YTHDC1 (0.46) | AGERCYP3A4CYP2C9CYP2C19MTNR1A | |
| SCHEMBL13734229 | 0.83 | YTHDC1 (0.46) | AGERCYP3A4CYP2C9CYP2C19MTNR1A | |
| SCHEMBL28158343 | 0.82 | CYP3A4 (0.45) | AGERCYP3A4CYP2C9CYP2C19MTNR1A | |
| SCHEMBL566741 | 0.81 | AGER (0.49) | AGERMTNR1ACTSDCHRM2CHRM3 | |
| SCHEMBL2814615 | 0.81 | AGER (0.67) | AGERMTNR1ACTSDCHRM2CHRM3 | |
| SCHEMBL5431901 | 0.81 | AGER (0.55) | AGERMTNR1ACTSDCHRM2CHRM3 | |
| SCHEMBL5436734 | 0.81 | AGER (0.55) | AGERMTNR1ACTSDCHRM2CHRM3 | |
| SCHEMBL3370759 | 0.79 | AGER (0.55) | AGERMTNR1ACTSDCHRM2CHRM3 | |
| SCHEMBL16320882 | 0.78 | L3MBTL1 (0.39) | CYP3A4CYP2C9CYP2C19L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822137-B2 | Phosphonucleosides useful in the treatment of viral disorders | UNIVERSITY COLLEGE CORK (IE) | 2017-11-21 | — | — | US | disclosed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | disclosed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | disclosed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | AGER 1067/4885CYP3A4 3982/4885CYP2C9 4436/4885 |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | ENTPD5, PNP, MTAP | AGER 4684/4885CYP3A4 4261/4885CYP2C9 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.